MAP4K1 Antibody

What is MAP4K1 and why is it important in research?

MAP4K1 (Mitogen-activated protein kinase kinase kinase kinase 1), also known as HPK1 (Hematopoietic progenitor kinase), is a serine/threonine kinase that plays crucial roles in multiple cellular processes. It functions in environmental stress response, acts upstream of the JUN N-terminal pathway, and serves as an activator of the Hippo signaling pathway . This pathway is pivotal in organ size control and tumor suppression by restricting proliferation and promoting apoptosis . MAP4K1 is particularly significant in hematopoietic lineage decisions, growth regulation, and T-cell activation . Recent research has also identified MAP4K1 as a novel TBK1 inhibitor linked to innate immunity, suggesting it as a potential therapeutic target for autoimmune diseases .

What are the main applications of MAP4K1 antibodies in scientific research?

MAP4K1 antibodies are employed across multiple research applications:

MAP4K1 antibodies have been validated in various human cell lines, particularly hematopoietic cell lines like Jurkat and Raji, reflecting MAP4K1's prominence in hematopoietic tissues .

How should researchers optimize Western blot protocols for MAP4K1 detection?

For optimal Western blot detection of MAP4K1, follow these research-validated steps:

• Sample preparation: Use 20-40 μg of protein for SDS-PAGE separation, prioritizing samples from hematopoietic tissues or cell lines (e.g., Jurkat, Raji) .

• Transfer conditions: Transfer to nitrocellulose membranes following standard protocols for proteins in the 90-91 kDa range .

• Antibody incubation:

  • Primary antibody: Dilute MAP4K1 antibody 1:1000-1:8000 (antibody-dependent) and incubate overnight at 4°C .

  • Secondary antibody: Use horseradish peroxidase-linked secondary antibody for 1 hour at room temperature .

• Visualization: Employ chemiluminescence for target protein visualization. For quantification, use appropriate image analysis software (e.g., VisionWork LS) .

• Expected molecular weight: Look for bands at approximately 90-91 kDa, which corresponds to the calculated molecular weight of MAP4K1 (91 kDa) .

Researchers should note that experimental conditions may require optimization based on specific antibody characteristics and sample types.

What are the critical considerations for immunohistochemistry using MAP4K1 antibodies?

For successful immunohistochemical detection of MAP4K1, researchers should consider:

• Antigen retrieval method: Most protocols recommend TE buffer pH 9.0 for optimal antigen retrieval. Alternatively, citrate buffer pH 6.0 may be used, though efficacy may vary .

• Antibody dilution: Start with a dilution range of 1:50-1:500, with optimization based on signal-to-noise ratio in your specific tissue type .

• Tissue selection: Validated positive controls include human tonsillitis tissue and human liver tissue, reflecting tissues with known MAP4K1 expression .

• Expression pattern: MAP4K1 is primarily expressed in hematopoietic organs including bone marrow, spleen, and thymus, with very low expression in lung, kidney, mammary glands, and small intestine .

• Controls: Include both positive controls (tissues known to express MAP4K1) and negative controls (antibody diluent only) to validate staining specificity.

Each antibody may require specific optimization, and researchers should perform titration experiments to determine optimal conditions for their specific research application.

How can MAP4K1 antibodies be utilized to study its role in cancer progression?

MAP4K1 has emerged as a significant player in multiple cancer types, and antibodies can be strategically employed to investigate its oncogenic functions:

• Expression correlation studies: Use MAP4K1 antibodies for IHC to analyze expression patterns across tumor samples and correlate with clinical outcomes. Research has shown MAP4K1 functions as a tumor promoter in glioblastoma multiforme and acute myeloid leukemia (AML) .

• Cellular proliferation mechanisms: Combine MAP4K1 knockdown/knockout approaches with antibody-based detection to investigate how MAP4K1 affects cancer cell proliferation. Studies have demonstrated that MAP4K1 knockdown significantly reduces cell proliferation in glioblastoma cell lines .

• Signaling pathway investigation: Use phospho-specific antibodies (such as MAP4K1-T165) alongside total MAP4K1 antibodies to dissect activation states in tumors. Research has revealed MAP4K1 regulates PI3K-AKT signaling to control cytokine receptor expression in glioblastoma .

• Drug resistance mechanisms: Employ MAP4K1 antibodies to study its role in chemoresistance. Studies have identified MAP4K1 overexpression as a mechanism of Homoharringtonine resistance in AML, modulating cell cycle through MAPK and DNA damage/repair pathways .

• Prognostic biomarker validation: Use standardized IHC protocols with MAP4K1 antibodies to evaluate its potential as a prognostic biomarker. Research has established that MAP4K1 overexpression is an independent risk factor predicting poor prognosis in AML .

These applications demonstrate how MAP4K1 antibodies can significantly contribute to understanding cancer biology beyond simple protein detection.

What is the role of MAP4K1 in immune modulation and how can antibodies help elucidate these mechanisms?

MAP4K1 serves as a critical immune regulatory molecule, and strategic antibody applications can reveal its complex immunomodulatory functions:

• T-cell activation studies: MAP4K1 antibodies can help monitor protein levels during T-cell activation processes. Recent research utilizing the selective MAP4K1 inhibitor BAY-405 demonstrated that MAP4K1 inhibition enhances T-cell immunity and overcomes suppressive effects of PGE2 and TGFβ in the tumor microenvironment .

• Innate immunity regulation: MAP4K1 antibodies can track protein expression changes during antiviral responses. Studies have identified MAP4K1 as an inhibitor of cytosolic RNA-induced antiviral signaling, representing a novel TBK1 inhibitor with significant implications for innate immunity .

• Tumor microenvironment analysis: Multiplexed IHC with MAP4K1 antibodies can examine its expression in tumor-infiltrating lymphocytes. Research has shown MAP4K1 inhibition in tumor-bearing mice results in T-cell-dependent antitumor efficacy, particularly when combined with PD-L1 blockade .

• Signaling cascade examination: Combining MAP4K1 antibodies with phospho-specific antibodies targeting downstream molecules helps map complete signaling pathways. Studies have revealed MAP4K1's regulation of MAPK pathways and DNA damage responses .

• Therapeutic target validation: MAP4K1 antibodies are essential for validating MAP4K1 as a potential therapeutic target. Research has demonstrated that MAP4K1 inhibition, when combined with PD-L1 blockade, results in superior antitumor impacts, illustrating complementarity of these approaches .

These applications illustrate how MAP4K1 antibodies serve as critical tools for understanding complex immune regulation mechanisms with therapeutic implications.

How can researchers address specificity concerns with MAP4K1 antibodies?

Ensuring MAP4K1 antibody specificity is crucial for valid experimental outcomes. Researchers should implement these strategies:

• Validation with knockout/knockdown controls:

  • Generate MAP4K1-KD or MAP4K1−/− cells (e.g., using CRISPR/Cas9 as demonstrated in T98G cells)

  • Compare antibody reactivity between wildtype and knockout samples

  • Verify complete absence of signal in knockout samples at the expected molecular weight

• Cross-reactivity assessment:

  • Test antibody against related MAP4K family members

  • Pay particular attention to MAP4K3, which shows structural similarity to MAP4K1 and has overlapping functions in T-cell responses

  • Consult kinase selectivity data when available (e.g., BAY-405 studies showed modest selectivity ratio of 6.5 for MAP4K1 vs MAP4K3)

• Multiple antibody validation:

  • Compare results using different antibodies targeting distinct MAP4K1 epitopes

  • Consider using both monoclonal (e.g., ab33910) and polyclonal (e.g., 23950-1-AP) antibodies

  • Verify consistent detection patterns across antibodies

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide

  • Observe elimination of specific signal

  • Particularly useful for phospho-specific antibodies like MAP4K1-T165

• Validated positive controls:

  • Include known MAP4K1-expressing samples (e.g., Jurkat or Raji cells for Western blot, human tonsillitis tissue for IHC)

  • Use tissues with established expression patterns (bone marrow, spleen, thymus)

These approaches collectively establish confidence in antibody specificity, which is essential for reliable data interpretation.

What are the most common technical challenges when using MAP4K1 antibodies and how can they be overcome?

Researchers working with MAP4K1 antibodies frequently encounter several technical challenges that can be addressed with these evidence-based solutions:

• Inconsistent Western blot detection:

  • Challenge: Variable band intensity or multiple bands

  • Solution: Optimize protein extraction using buffers containing phosphatase inhibitors, as MAP4K1 undergoes extensive phosphorylation

  • Evidence: Studies show MAP4K1 can autophosphorylate, affecting antibody recognition

• Low signal in immunohistochemistry:

  • Challenge: Weak or absent staining despite confirmed expression

  • Solution: Test alternative antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0)

  • Evidence: Published protocols indicate MAP4K1 epitopes are sensitive to retrieval conditions

• Background in immunoprecipitation:

  • Challenge: Non-specific protein pull-down

  • Solution: Use 0.5-4.0 μg antibody per 1.0-3.0 mg protein lysate, and include pre-clearing steps

  • Evidence: Validated IP protocols for MAP4K1 from Jurkat cells demonstrate successful enrichment with these ratios

• Phosphorylation state interference:

  • Challenge: Antibody recognition affected by phosphorylation status

  • Solution: Use phospho-specific antibodies (like MAP4K1-T165) for studying activation, alongside total MAP4K1 antibodies

  • Evidence: Phosphorylation at T165 affects MAP4K1 activity and can influence antibody binding

• Cell type-dependent expression:

  • Challenge: Variable detection across different cell types

  • Solution: Focus on hematopoietic cell lines (Jurkat, Raji) for initial validation; adjust protein loading for tissues with lower expression

  • Evidence: MAP4K1 is primarily expressed in hematopoietic tissues with minimal expression in other tissues

These targeted approaches address specific technical limitations, increasing the reliability and reproducibility of MAP4K1 antibody-based experiments.

How should researchers interpret discrepancies between MAP4K1 mRNA and protein expression data?

When faced with discrepancies between MAP4K1 mRNA and protein levels, researchers should consider these analytical approaches:

• Post-transcriptional regulation assessment:

  • Evaluate potential microRNA regulation of MAP4K1

  • Analyze mRNA stability using actinomycin D chase experiments

  • Research has demonstrated that various regulatory mechanisms affect translation efficiency of MAP4K1

• Protein stability analysis:

  • Examine protein half-life using cycloheximide pulse-chase experiments

  • Consider proteasomal degradation pathways

  • Studies of MAP4K1 in cancer cells suggest altered protein stability contributes to expression differences

• Cell-specific translation efficiency:

  • Compare polysome profiles between cell types showing discrepancies

  • Evaluate ribosome occupancy on MAP4K1 mRNA

  • Research shows translation efficiency varies significantly across tissue types for many kinases

• Splice variant consideration:

  • Use antibodies targeting different epitopes to detect potential splice variants

  • Perform RT-PCR to identify alternative transcripts

  • Different MAP4K1 antibodies may recognize distinct protein isoforms

• Methodological validation:

  • Ensure qPCR primer specificity using melt curve analysis

  • Verify antibody specificity with appropriate controls

  • Research protocols emphasize the importance of analyzing specificity of PCR products using melt-curve analysis

These analytical approaches help researchers distinguish biological phenomena from technical artifacts when interpreting MAP4K1 expression data.

What experimental approaches can differentiate between MAP4K1 expression and activation in complex biological samples?

Distinguishing MAP4K1 expression from its activation state requires sophisticated experimental strategies:

• Phospho-specific antibody application:

  • Use antibodies targeting specific phosphorylation sites (e.g., MAP4K1-T165)

  • Compare phospho-MAP4K1 to total MAP4K1 levels

  • Phosphorylation at T165 has been established as a key regulatory modification

• Kinase activity assays:

  • Immunoprecipitate MAP4K1 and measure kinase activity in vitro

  • Monitor phosphorylation of known substrates

  • Research has utilized this approach to correlate MAP4K1 expression with functional activity

• Pathway analysis with phospho-specific antibody panels:

  • Examine downstream effectors (phospho-JNK, phospho-c-Jun, phospho-ERK)

  • Compare activation patterns across experimental conditions

  • Studies demonstrate MAP4K1 regulates these pathways in cancer and immune cells

• Chromatin immunoprecipitation (ChIP) for transcriptional activity:

  • Use ChIP to assess MAP4K1-mediated transcriptional regulation

  • Analyze promoter occupancy of downstream genes

  • Research has employed ChIP assays to study MAP4K1's role in gene regulation

• Functional readouts in relevant systems:

  • Measure MAP4K1-dependent cellular processes (proliferation, apoptosis)

  • Compare effects of MAP4K1 knockdown versus inhibition

  • Studies in glioblastoma and AML cells demonstrate how these approaches can distinguish expression from activation

These complementary approaches provide a comprehensive assessment of MAP4K1's functional status beyond simple expression analysis.

How can MAP4K1 antibodies contribute to cancer immunotherapy research?

MAP4K1 antibodies enable several cutting-edge applications in cancer immunotherapy research:

• Monitoring MAP4K1 inhibition efficacy:

  • Use antibodies to measure target engagement of MAP4K1 inhibitors like BAY-405

  • Assess phosphorylation status changes of MAP4K1 and downstream targets

  • Research demonstrates BAY-405 enhances T-cell immunity and overcomes suppressive effects of PGE2 and TGFβ in the tumor microenvironment

• Combination therapy biomarker development:

  • Apply MAP4K1 antibodies to identify patients likely to benefit from combined MAP4K1 inhibition and immune checkpoint blockade

  • Research shows MAP4K1 inhibition with PD-L1 blockade results in superior antitumor impacts

• Tumor microenvironment analysis:

  • Use multiplex immunofluorescence with MAP4K1 antibodies to characterize immune cell populations

  • Correlate MAP4K1 expression with immune activation/suppression markers

  • Studies have identified MAP4K1 as regulating cytokine-cytokine receptor interactions and chemokine signaling pathways

• Resistance mechanism investigation:

  • Monitor MAP4K1 expression changes during immunotherapy resistance development

  • Compare pre- and post-treatment samples

  • MAP4K1 has been implicated in drug resistance mechanisms in AML

• Cell-based therapy optimization:

  • Use MAP4K1 antibodies to assess genetic manipulation efficacy in adoptive cell therapies

  • Track MAP4K1 expression/activity in engineered T-cells

  • MAP4K1 modulation affects T-cell reactivity and antitumor responses

These applications highlight how MAP4K1 antibodies contribute to advancing our understanding of immunotherapy mechanisms and developing more effective cancer treatments.

What are the considerations for using MAP4K1 antibodies in studying its role in the antiviral immune response?

When investigating MAP4K1's role in antiviral immunity, researchers should consider these specialized approaches:

• Temporal expression analysis during viral challenge:

  • Track MAP4K1 protein levels at different timepoints after viral infection

  • Compare expression patterns across different viral challenges

  • Research has identified MAP4K1 as an inhibitor of cytosolic RNA-induced antiviral signaling

• Co-localization studies with innate immune sensors:

  • Perform immunofluorescence with MAP4K1 antibodies alongside viral sensors (RIG-I, MDA5)

  • Analyze subcellular localization changes during infection

  • MAP4K1's interaction with TBK1 suggests potential spatial regulation of antiviral responses

• Pathway-specific activation analysis:

  • Use phospho-specific antibodies to monitor MAP4K1 activation during viral infection

  • Correlate with type I interferon production

  • Studies have established MAP4K1 as a novel TBK1 inhibitor linked to innate immunity

• Genetic variation impact assessment:

  • Compare MAP4K1 expression and activity across individuals with different susceptibility to viral infection

  • Correlate with disease outcomes

  • This approach could identify novel biomarkers for antiviral response prediction

• Autoimmunity connection evaluation:

  • Use MAP4K1 antibodies to study its role in autoimmune conditions triggered by viral infections

  • Compare expression in autoimmune patient samples versus controls

  • Research suggests MAP4K1 as a potential therapeutic target for autoimmune diseases